DK2576776T3 - Modificerede beta-lactamaser og fremgangsmåder og anvendelser relateret dertil - Google Patents

Modificerede beta-lactamaser og fremgangsmåder og anvendelser relateret dertil Download PDF

Info

Publication number
DK2576776T3
DK2576776T3 DK11786185.6T DK11786185T DK2576776T3 DK 2576776 T3 DK2576776 T3 DK 2576776T3 DK 11786185 T DK11786185 T DK 11786185T DK 2576776 T3 DK2576776 T3 DK 2576776T3
Authority
DK
Denmark
Prior art keywords
beta
lactamase
amino acid
seq
sequence
Prior art date
Application number
DK11786185.6T
Other languages
English (en)
Inventor
Pertti Koski
Ulla Airaksinen
Katja VÄLIMÄKI
Original Assignee
Synthetic Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthetic Biologics Inc filed Critical Synthetic Biologics Inc
Application granted granted Critical
Publication of DK2576776T3 publication Critical patent/DK2576776T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)

Claims (18)

1. Beta-lactamase, der omfatter en aminosyresekvens, der er mindst 80 % sekvensidentisk med SEQ ID NO: 1, kendetegnet ved, at beta-lactamasen har en hydrofil aminosyrerest, der ikke er en asparaginsyre (D), i en position svarende til position 276 ifølge Ambler-klassifikationen og den hydrofile aminosyre er udvalgt fra arginin (R), histidin (H), lysin (K), asparagin (N), glutamin (Q), serin (S) og threonin (T), og hydrolyserer penicilliner og/eller cephalosporiner.
2. Fremgangsmåde til modificering af en beta-lactamase, der omfatter en aminosyresekvens, der er mindst 80 % sekvensidentisk med SEQ ID NO: 1, kendetegnet ved, at en aminosyre af beta-lactamasen ved en position af SEQ ID NO: 1 svarende til position 276 ifølge Ambler-klassifikationen er erstattet med en hydrofil aminosyre, der ikke er en asparaginsyre (D), og den hydrofile aminosyre er udvalgt fra arginin (R), histidin (H), lysin (K), asparagin (N), glutamin (Q), serin (S), og threonin (T) for at opnå en beta-lactamase, der hydrolyserer penicilliner og/eller cephalosporiner.
3. Beta-lactamase ifølge krav 1, hvor beta-lactamasen omfatter en aminosyresekvens, der er mindst 90 % sekvensidentisk med SEQ ID NO: 1.
4. Beta-lactamase ifølge krav 1 eller fremgangsmåde ifølge krav 2 kendetegnet ved, at aminosyren i positionen SEQ ID NO: 1 svarende til position 276 er asparagin (N).
5. Beta-lactamase ifølge krav 1 eller fremgangsmåde ifølge krav 2 kendetegnet ved, at aminosyren i positionen af SEQ ID NO: 1 svarende til position 276 er arginin (R).
6. Beta-lactamase eller fremgangsmåde ifølge et hvilket som helst af de foregående krav kendetegnet ved, at den hydrofile aminosyre ved position af SEQ ID NO: 1 svarende til position 276 befinder sig i en alpha-helix.
7. Beta-lactamase eller fremgangsmåde ifølge et hvilket som helst af de foregående krav kendetegnet ved, at beta-lactamasen endvidere omfatter mindst én aminosyre, der er udvalgt fra gruppen bestående af Leu220 og Arg244 ifølge Ambler-klassifikationen.
8. Beta-lactamase eller fremgangsmåde ifølge et hvilket som helst af de foregående krav kendetegnet ved, at beta-lactamasen har forbedret katalytisk effektivitet på cephalosporiner sammenlignet med beta-lactamasen af SEQ ID NO: 1, der har asparaginsyre (D) ved positionen svarende til position 276 ifølge Amber-klassifikationen.
9. Beta-lactamase ifølge krav 1 eller fremgangsmåde ifølge krav 2 kendetegnet ved, at cephalosporinerne er udvalgt fra gruppen bestående af cefoperazon, ceftriaxon og cefazolin.
10. Fremgangsmåde til fremstilling af beta-lactamasen ifølge et hvilket som helst af kravene 1 eller 3-9 kendetegnet ved, at fremgangsmåden omfatter følgende trin: i) tilvejebringelse af et gen, der koder for beta-lactamasen ifølge et hvilket som helst af kravene 1 eller 3-9; ii) transformering af en værtscelle med genet; iii) opnåelse af en værtscelle, der fremstiller beta-lactamasen; iv) indvinding af beta-lactamasen.
11. Polynukleotid kendetegnet ved, at det omfatter en sekvens ifølge et hvilket som helst af SEQ ID NO: 2 eller 4 eller en degenereret variant deraf, eller det koder for beta-lactamasen ifølge et hvilket som helst af kravene 1 eller 3-9.
12. Værtscelle, der omfatter polynukleotidet ifølge krav 11.
13. Farmaceutisk sammensætning, der omfatter beta-lactamasen ifølge et hvilket som helst af kravene 1 eller 3-9.
14. Beta-lactamase ifølge et hvilket som helst af kravene 1 eller 3-9 til anvendelse som et medikament.
15. Anvendelse af beta-lactamasen ifølge et hvilket som helst af kravene 1 eller 3-9 til fremstilling af et medikament til behandling eller forebyggelse af beta-lactam-antibiotikainducerede bivirkninger i fordøjelseskanalen.
16. Anvendelse ifølge krav 15 kendetegnet ved, at beta-lactamase(r) administreres oralt.
17. Anvendelse ifølge krav 15 kendetegnet ved, at beta-lactamase(r) administreres direkte til en patients fordøjelseskanal.
18. Anvendelse ifølge et hvilket som helst af kravene 15-17 kendetegnet ved, at beta-lactamase(r) og beta-lactam-antibiotika administreres sammen i form af en syreresistent pille til et individ.
DK11786185.6T 2010-05-24 2011-05-17 Modificerede beta-lactamaser og fremgangsmåder og anvendelser relateret dertil DK2576776T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20105572A FI20105572A0 (fi) 2010-05-24 2010-05-24 Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
PCT/FI2011/050450 WO2011148041A1 (en) 2010-05-24 2011-05-17 Modified beta-lactamases and methods and uses related thereto

Publications (1)

Publication Number Publication Date
DK2576776T3 true DK2576776T3 (da) 2016-10-03

Family

ID=42234353

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11786185.6T DK2576776T3 (da) 2010-05-24 2011-05-17 Modificerede beta-lactamaser og fremgangsmåder og anvendelser relateret dertil

Country Status (16)

Country Link
US (11) US9034602B2 (da)
EP (1) EP2576776B1 (da)
JP (1) JP5827681B2 (da)
KR (1) KR101708703B1 (da)
CN (1) CN103038341B (da)
AU (1) AU2011257092C1 (da)
BR (1) BR112012030029B1 (da)
CA (1) CA2800671C (da)
DK (1) DK2576776T3 (da)
ES (1) ES2588279T3 (da)
FI (1) FI20105572A0 (da)
HU (1) HUE030689T2 (da)
PL (1) PL2576776T3 (da)
RU (1) RU2570551C2 (da)
WO (1) WO2011148041A1 (da)
ZA (1) ZA201208948B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8992422B2 (en) 2006-03-23 2015-03-31 Ethicon Endo-Surgery, Inc. Robotically-controlled endoscopic accessory channel
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
BR112016023360B1 (pt) * 2014-04-17 2023-03-07 Synthetic Biologics, Inc Beta-lactamase e seu uso
JP6803328B2 (ja) 2014-08-28 2021-01-06 シンセティック バイオロジクス，インコーポレイテッド 大腸菌ベースでのベータラクタマーゼ生産
WO2016057744A1 (en) 2014-10-08 2016-04-14 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
FR3027307B1 (fr) * 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
EP3236993B1 (en) 2014-12-23 2023-09-13 Theriva Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
EP3261662B1 (en) 2015-02-23 2021-07-21 Synthetic Biologics Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
EP3265119B1 (en) 2015-03-06 2023-10-11 Theriva Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
JP6845258B6 (ja) * 2016-02-23 2021-04-28 ダ・ボルテラ ベータ−ラクタマーゼ変異体
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
CN109562147B (zh) * 2016-06-28 2023-09-01 特里瓦生物制剂有限公司 保护微生物组免受口服抗生素
US20190275120A1 (en) * 2016-11-01 2019-09-12 Synthetic Biologics, Inc. Methods and compositions for attenuating antibiotic resistance
CN110157699B (zh) * 2018-02-12 2021-07-23 中国科学院微生物研究所 β-内酰胺酶及其编码基因以及它们的应用
US20210290741A1 (en) 2018-08-05 2021-09-23 Da Volterra Compositions for the treatment of graft versus host disease
AU2019317986A1 (en) 2018-08-05 2021-02-11 Da Volterra Method for improving anticancer agent efficacy
CN110777178A (zh) * 2019-12-02 2020-02-11 河北慧林生物科技有限公司 固定化羧基酯水解酶在氯唑西林、双氯西林、氟氯西林及苯唑西林侧链合成中的应用
CN114075560A (zh) * 2020-08-18 2022-02-22 杭州俊丰生物工程有限公司 一种β-内酰胺酶的稳定组合物
EP4148136A1 (en) 2021-09-08 2023-03-15 Da Volterra An engineered yeast cell for the delivery of antibiotic-inactivating enzymes

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL89987C (da) 1954-05-29
US2941995A (en) 1957-08-02 1960-06-21 Beecham Res Lab Recovery of solid 6-aminopenicillanic acid
US2982696A (en) 1959-05-01 1961-05-02 Schenley Ind Inc Ion-exchange procedures for the purification of penicillinase
US3070511A (en) 1960-02-10 1962-12-25 Lepetit Spa Process for preparing 6-aminopenicillanic acid
US3150059A (en) 1962-12-26 1964-09-22 Lilly Co Eli Penicillin deacylation via actinoplanaceae fermentation
US3239394A (en) 1964-06-15 1966-03-08 Merck & Co Inc Process for producing 7-amino-cephalosporanic acid
US3499909A (en) 1966-05-18 1970-03-10 Koninklijke Gist Spiritus Process for production of 6-aminopenicillanic acid
US3488729A (en) 1966-08-22 1970-01-06 Lilly Co Eli Cephalothin ester
GB1241844A (en) 1968-08-23 1971-08-04 Beecham Group Ltd Penicillins
GB1463513A (en) 1974-08-13 1977-02-02 Beecham Group Ltd Enzymes
FI59265C (fi) 1974-08-13 1981-07-10 Beecham Group Ltd Foerfarande foer framstaellning av 6-aminopenicillansyra
GB2199582A (en) 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CA2007083A1 (en) 1989-01-09 1990-07-09 Nobuhiko Katunuma Pharmaceutical use of trypstatin
CS275231B2 (en) 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle
FI920206A0 (fi) 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
CN1190434A (zh) 1995-07-07 1998-08-12 诺沃挪第克公司 用不能形成芽孢的芽孢杆菌生产蛋白质的方法
US7585674B2 (en) 2001-05-29 2009-09-08 Kao Corporation Host microorganisms
FI112666B (fi) 2001-11-06 2003-12-31 Ipsat Therapies Oy Itiöimätön Bacillus subtilis, sen valmistus ja käyttö
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
US7323303B2 (en) * 2003-03-31 2008-01-29 Hong Kong Polytechnic University Modified β-lactamases and uses thereof
EP1564286A1 (en) 2004-02-11 2005-08-17 Université de Liège Hybrid proteins of beta-lactamase class A
IL163821A0 (en) * 2004-08-31 2005-12-18 Ravgalai Ltd Rapax Consortium Software for management of legal motions Methods and kits for the detection of biotoxic andantibiotic residues
ES2429095T3 (es) 2005-05-18 2013-11-13 Da Volterra Aporte colónico de adsorbentes
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
FI119678B (fi) 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt

Also Published As

Publication number Publication date
US9301995B2 (en) 2016-04-05
WO2011148041A1 (en) 2011-12-01
US8894994B2 (en) 2014-11-25
EP2576776A4 (en) 2014-01-22
EP2576776A1 (en) 2013-04-10
HUE030689T2 (en) 2017-05-29
AU2011257092C1 (en) 2014-06-19
US20140127785A1 (en) 2014-05-08
US9587234B2 (en) 2017-03-07
BR112012030029A2 (pt) 2017-05-02
US20130216622A1 (en) 2013-08-22
US10253306B2 (en) 2019-04-09
US10041056B2 (en) 2018-08-07
HK1183905A1 (zh) 2014-01-10
CN103038341A (zh) 2013-04-10
RU2012155420A (ru) 2014-06-27
US20220090044A1 (en) 2022-03-24
US20150056178A1 (en) 2015-02-26
CA2800671C (en) 2018-09-18
BR112012030029B1 (pt) 2021-08-17
ZA201208948B (en) 2014-02-26
US20150209418A1 (en) 2015-07-30
US20190169590A1 (en) 2019-06-06
ES2588279T3 (es) 2016-10-31
KR101708703B1 (ko) 2017-02-21
JP2013529905A (ja) 2013-07-25
US20160168557A1 (en) 2016-06-16
EP2576776B1 (en) 2016-07-13
JP5827681B2 (ja) 2015-12-02
AU2011257092B2 (en) 2013-12-19
FI20105572A0 (fi) 2010-05-24
US9034602B2 (en) 2015-05-19
US20170327812A1 (en) 2017-11-16
KR20130133648A (ko) 2013-12-09
AU2011257092A1 (en) 2013-01-10
CA2800671A1 (en) 2011-12-01
US20160230160A1 (en) 2016-08-11
US20170145402A1 (en) 2017-05-25
RU2570551C2 (ru) 2015-12-10
US20230332128A1 (en) 2023-10-19
PL2576776T3 (pl) 2017-01-31
US9765320B2 (en) 2017-09-19
US11214787B2 (en) 2022-01-04
US9301996B2 (en) 2016-04-05
CN103038341B (zh) 2016-04-20

Similar Documents

Publication Publication Date Title
US20230332128A1 (en) Modified beta-lactamases and methods and uses related thereto
KR101609243B1 (ko) 변형 베타-락타마제 및 이의 제조 방법
CN101563099A (zh) β-内酰胺酶的用途
AU2014201082B2 (en) Modified beta-lactamases and methods and uses related thereto
HK1183905B (en) Modified beta-lactamases and methods and uses related thereto